X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Natoli NP-RD30 Included at Diosna ProcessLab

Content Team by Content Team
21st September 2020
in Drug Development, News
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The Diosna Dierks & Söhne GmbH recently opened the “Diosna ProcessLab” located in Osnabrück, Germany. The lab, which was completed in April 2020, offers research and formulation trials as well as virtual and in-person training classes. It offers an overview of the different system options and various possibilities for experimental implementation.

The NP-RD30 Rotary Tablet Press

One of the systems included in the Diosna ProcessLab is the Natoli NP-RD30, which is designed to help solve formulation and scale-up challenges. The multi-functional rotary tablet press replicates the design and functionality of a full-scale production press with the analytical capabilities of an R&D machine.

The NP-RD30 helps to get products to market faster with the data acquisition, analysis, and scalability features included in its user-friendly interface. The NP-RD30 is 21 CFR Part 11 compliant. It comes with an intuitive 21” HMI touchscreen and USB port for data transfer. Rolling casters allow for easy mobility of the machine. The NP-RD30 is equipped with an integrated duel vacuum system, a built-in calibration tool, upper and lower punch seals, powder recirculation system, and self-adjusting lower punch retainers with an exclusive push button feature.

Efficient and Dependable

An optimized fast-fill cam design creates a vacuum to assist in die filling for more consistent tablet weights. The NP-RD30 is designed with same diameter pre- and main compression rollers, independent overload, ejection, and take-off force monitoring. While designed to meet the needs of research and development, the NP-RD30 can also be used as a small batch production press with efficient and dependable standard batch reporting.

The NP-RD30 will be used to help enable the complete production of tablets for seminars, training, and more. The tablet press completes the manufacturing process chain at the Diosna ProcessLab that starts with powder mixing, granulation, final blending, tableting (completed with the NP-RD30), and finally, coating of the tablets. Customers who perform formulation trials at Diosna ProcessLab, are able to compress the granules to tablets, getting the opportunity to handle and analyze the quality of the final tablet with all its physical and chemical characteristics.

The first seminar in the new Diosna ProcessLab, “PTS-Seminar: Intensive Training Wet Granulation,” is planned for October 28-29, 2020 depending on availability of the Diosna ProcessLab due to current global circumstances. The number of attendees has been reduced to provide a safe environment in accordance with the Good Manufacturing Practice (GMP) standards with the World Health Organization (WHO). The Diosna ProcessLab and the equipment was also built according to GMP standards.

Previous Post

OncoImmune, Inc. Raises $56 Million Series B Financing for Novel Cancer and COVID-19 Therapeutics

Next Post

DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In